Journal Article Summary
The article investigates the impact of omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on the progression of coronary artery plaque in patients with coronary artery disease who are already on statin therapy. This topic is significant because even with effective statin treatment, many patients still face a high risk of cardiovascular events due to the progression of atherosclerotic plaque. Understanding how omega-3 fatty acids can influence plaque development could provide additional strategies for reducing cardiovascular risks in these patients.
In this study, 218 participants with stable coronary artery disease were randomly assigned to receive either high-dose omega-3 supplements (3.36 grams daily) or no omega-3 for 30 months. The researchers measured changes in coronary plaque volume using advanced imaging techniques and assessed plasma levels of EPA and DHA. The findings revealed that patients who achieved an omega-3 fatty acid index of 4% or higher experienced a significant prevention of plaque progression compared to those with lower levels, particularly among nondiabetic participants.
However, the study has limitations, including the lack of data on the effects of omega-3 fatty acids on patients with diabetes and the potential variability in individual responses to omega-3 supplementation. Patients should consult their healthcare providers about their omega-3 levels and discuss whether increasing omega-3 intake could be beneficial for their heart health. It is essential to consider these findings within the broader context of cardiovascular care and not as a standalone solution.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Alfaddagh Abdulhamied, Elajami Tarec K., Saleh Mohamad, Mohebali Donya, Bistrian Bruce R., Welty Francine K.. An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. Atherosclerosis 2019. DOI: 10.1016/j.atherosclerosis.2019.04.213. PMID: 31055222. PMCID: PMC7963401.
Featured Pill Pals Product
Omega 3 Acid Ethyl Esters --- 1 Gram --- Generic For Lovaza --- Epic Pharma
Omega 3 Acid Ethyl Esters — 1 Gram — Generic For Lovaza — Epic Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
